Keytruda

CAS: 1374853-91-4

As a humanized anti-pd1 monoclonal antibody, palmdrine (mk-3475, commodity

name Keytruda, MSD) was approved by the food and drug administration (FDA) in

September 2014 for the treatment of advanced or unresectable malignant melanoma

as an immune checkpoint inhibitor (ICB). However, it has been found that pd-1

inhibitors can produce the side effects of autoimmune injury to the human body’s

multiple systems, such as hepatitis, pneumonia and myocardial injury.

Adaptation disease

1) unresectable or metastatic melanoma and plymma after disease progression and,

such as BRAF V600 positive mutation.
2) fda-approved tests identified metastatic NSCLC and disease progression after

chemotherapy with or with platinum-based chemotherapy. Patients treated with KEYTRUDA

before fda-approved therapy had EGFR or ALK genomic tumor distortion in these patients.